BACKGROUND FFR measurement is beneficial to evaluate the functional significance of coronary artery stenosis and guiding coronary interventions. The ACIST Navvus Ò Microcatheter is a rapid exchange intravascular catheter that can be passed into the coronary tree over any 0.014" guidewire. The Navvus catheter has an in-lesion mean distal shaft diameter of 0.022" with a maximum profile of 0.036" at the pressure sensor near the distal tip.
METHODS We compared FFR values measured with a new catheter based pressure sensor to those measured with a traditional 0.014" wire-based system (Volcano) across a wide range of stenosis severities in 17 patients with ischemic heart disease. After diagnostic angiography, FFR was obtained by both commercially available 0.014" pressure wire (Volcano Verrata Ò ) and catheter based pressure sensor (ACIST Navvus Ò ). Values were obtained in a sequential fashion over several minutes under separate vasodilator administration, with sensors placed independently in similar locations.
RESULTS Among 29 measurements (pre-PCI:20, post-PCI:9), successful FFR measurement was obtained in 28/29 cases with the microcatheter system, and 28/29 cases with the wire based system. Both cases where FFR was unsuccessful involved tortuous lesions. The correlation of FFR values between both system was quite good and acceptable across the wide range of stenosis severities (see figure) , with a predicted bias at the 0.80 cut point of 0.004, wire-based system higher, (95% CI -0.02 to 0.02), by Passing-Bablok analysis.
CONCLUSIONS Navvus can navigate difficult anatomy with minimum drift phenomenon. FFR correlation was quite good even in very severe stenosis. BACKGROUND Fractional flow reserve (FFR) has become standard invasive assessment for determining the functional significance of coronary artery stenosis. Intravenous (IV) infusion of adenosine is the gold standard method for the induction of hyperemia. Intracoronary (IC) bolus injection of nicorandil, a coronary vasodilator which acts on both macro-and microvascular systems, has been reported to be safe and cardioprotective in patients with coronary artery disease.
METHODS We performed a patient-level pooled analysis of 5 previous studies, which compared FFR measurement using IV adenosine/ adenosine triphosphate (ATP) and IC nicorandil. A total of 480 intermediate coronary lesions from 429 patients were analyzed to evaluate the safety and efficacy of IC nicorandil as an alternative choice of hyperemic agent for invasive physiologic studies.
RESULTS IC nicorandil showed significantly earlier achievement of maximum hyperemia (time-to-the lowest FFR: 18.0s vs. 44.0s [IQR 36.0-60.0], p<0.001) with similar hyperemic efficacy, compared with intravenous (IV) adenosine/ATP (FFR 0.82[0.75-0.87] vs. 0.82[0.74-0.88], p¼0.207). FFR measurements with both agents showed excellent correlation and classification agreement (CA) for FFR 0.80 (r¼0.941, ICC 0.980, CA 90.8%, Kappa¼0.814, AUC of nicorandil 0.980, all p<0.001). Only 3 patients (0.7%) showed changes in classification across the gray zone (0.75-0.80). IC nicorandil produced fewer changes in blood pressure (BP) and heart rate (HR) and showed less chest pain than IV adenosine/ATP (all p<0.001). When comparing DFFR according to DBP or DHR between IV adenosine/ATP and IC nicorandil, there were no correlations, either between DFFR and DBP (r¼-0.114, p¼0.091), or between DFFR and DHR (r¼1.000, p¼0.151). measured and compared with the calculated FFR' d,pred . The accuracy was also compared with a previous model that did not consider a side branch flow.
RESULTS FFR' d,pred using our model (vs. previous model) showed a closer correlation with the measured FFR' d (R 2 ¼0.88 vs 0.80) and a greater prediction power in terms of mean absolute error (0.03AE0.02 vs 0.04AE0.03, p¼0.045), (Figure A and B) . When FFR gradients across proximal and distal stenosis were equal (DFFR p ¼DFFR d ), prioritizing treatment of distal (vs. proximal) stenosis was more effective to reduce the residual FFR gradient ( Figure C) . Especially in tandem lesions with a big side branch and a large sum of DFFR d and DFFR p , even with a slightly larger DFFR p (vs. DFFR d ), consequent FFR recovery was less effective compared to distal stenosis treatment ('disagreement zone' in Figure D) . CONCLUSIONS Our prediction model accurately predicts FFR' d after treatment of a stenosis and is useful to optimize treatment strategy in tandem lesion. Regadenoson, a selective A2A receptor agonist, is an approved hyperemic agent for pharmacological stress imaging, its role for measuring FFR is unknown. We therefore systematically reviewed published literature to compare the efficacy and safety between those two drugs in measuring FFR.
METHODS We searched PubMed, Cochrane Library & Web of Science for randomized controlled trials (RCT) comparing the use of Adenosine versus Regadenoson in measuring FFR. The primary endpoint was the correlation of FFR values using those two drugs. We also assessed the change in mean blood pressure, heart rate, and development of advanced heart block as safety outcomes. Odd ratio and 95% confidence intervals were used to evaluate categorical variables. Standard difference in the mean and 95% confidence intervals were used to evaluate continuous variables. All the analysis was done with the Der Simonian and Laird random effect model. Sensitivity and cumulative analysis were performed for each outcome.
RESULTS A total of 4 RCT with a total of 202 patients were included. Each patient underwent FFR measurement using IV Adenosine first then with IV Regadenoson. A strong linear correlation of FFR was noted in between the two methods. The pooled mean correlation factor was R 0.981. There was no statistically significant difference in mean FFR values between both groups (Sdm -0.87, CI ¼ [-1.08,-0.09], P¼ 0.07). The standard mean difference was lower with sensitivity analysis but remained statistically insignificant (Sdm -0.008, CI ¼ [-0.21,1.9], P¼0.94). Change in heart rate were less in Adenosine arm B118
